1-ethyl-4-phenyl-piperidin-4-ol | 86219-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-ethyl-4-phenyl-piperidin-4-ol
• 英文别名: 1-Aethyl-4-phenyl-piperidin-4-ol；1-Ethyl-4-phenylpiperidin-4-ol
• CAS: 86219-68-3
• 化学式: C₁₃H₁₉NO
• 分子量: 205.3
• InChiKey: WKITVSDIUPQIOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-ethyl-4-phenyl-piperidin-4-ol 、 丙酸酐 在 硫酸 作用下， 生成 propionic acid-(1-ethyl-4-phenyl-[4]piperidyl ester)
  参考文献：
  名称：

  PIPERIDINE DERIVATIVES. PART III. 4-ARYLPIPERIDINES¹

  摘要：

  DOI：

  10.1021/jo01170a022
• 作为产物：
  描述：

  N-乙基-4-哌啶酮 、 phenylmagnesium bromide 在 乙醚 作用下， 生成 1-ethyl-4-phenyl-piperidin-4-ol
  参考文献：
  名称：

  PIPERIDINE DERIVATIVES. PART III. 4-ARYLPIPERIDINES¹

  摘要：

  DOI：

  10.1021/jo01170a022

文献信息

• BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF
  申请人：Agency for Science, Technology and Research

  公开号：US20140371199A1

  公开（公告）日：2014-12-18

  The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.

  本发明涉及某些化合物（例如咪唑吡嗪、咪唑吡啶、咪唑吡嗪和咪唑嘧啶化合物），这些化合物作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物制备用于预防和治疗疾病（例如增生性疾病（例如癌症）、炎症性疾病、阿尔茨海默病）的药物的用途，以及治疗这些疾病的方法。
• NOVEL AZABICYCLOHEXANES
  申请人：Jain Rajseh

  公开号：US20120165320A1

  公开（公告）日：2012-06-28

  The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

  本发明涉及公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体包括R和S异构体，多晶型，前药，代谢物，盐或溶剂的形式。该发明还涉及用于合成公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体，多晶型，前药，代谢物，盐或溶剂的过程。
• Cannabinoid receptor ligands and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040214837A1

  公开（公告）日：2004-10-28

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
• Indenoisoquinolinone analogs and methods of use thereof
  申请人：Jagtap Prakash

  公开号：US20070049555A1

  公开（公告）日：2007-03-01

  The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.

  本发明涉及Indenoisoquinolinone类似物，包括有效量的Indenoisoquinolinone类似物的组合物，以及用于治疗或预防炎症性疾病、再灌注损伤、糖尿病、糖尿病并发症、器官移植引起的再氧化损伤、缺血状况、神经退行性疾病、肾功能衰竭、血管疾病、心血管疾病、癌症、早产并发症、心肌病、视网膜病、肾病、神经病、勃起功能障碍或尿失禁的方法，包括向需要治疗的受体内给予有效量的Indenoisoquinolinone类似物。
• [EN] BENZYLPYRROLIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] DÉRIVÉS DE BENZYLPYRROLIDINONE UTILES COMME MODULATEURS DE L'ACTIVITÉ DES RÉCEPTEURS DES CHIMIOKINES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011100227A1

  公开（公告）日：2011-08-18

  The present application describes modulators of MCP-1 or CCR-2 of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, n, W, X, R1 and R6, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.

  本申请描述了MCP-1或CCR-2的调节剂的公式（I）或其立体异构体或前药或药学上可接受的盐，其中m，n，W，X，R1和R6在此被定义。此外，本文还披露了使用公式（I）的调节剂治疗和预防炎症性疾病，如哮喘和过敏性疾病，以及自身免疫病理学，如类风湿性关节炎和移植排斥等的方法。